Abstract:BACKGROUND Hearing loss has not been thoroughly investigated as a comorbidity in larger cohorts of individuals with neurofibromatosis type 1 (NF1). METHODS Available audiometric data were reviewed from NF1 patients seen at a tertiary pediatric hospital to assess prevalence and risk factors for hearing loss. RESULTS Of 1172 patients with NF1 seen between 2010-2022, 90 had available audiometric data for review and 48/90 patients (53%) had ≥1 audiogram revealing hearing loss. Those not referred to audiology were presumed to have normal hearing, resulting in a conservative estimate of hearing loss of 4% (48/1,172) for children and young adults with NF1. Of the 90 patients with audiograms, 32% (29/90) had conductive loss (CHL), 17% (15/90) had sensorineural loss (SNHL), and 3% (3/90) had mixed hearing loss. Hearing loss type was undetermined for 1 patient. For children with conductive hearing loss, 6 had permanent CHL secondary to plexiform neurofibroma, 19 CHL were considered transient due to active middle ear dysfunction, and 4 CHL cases were indeterminate in etiology. For 3 children with SNHL or mixed hearing loss, etiology included history of ototoxic chemotherapy and/or family history of SNHL. In the 16 patients with SNHL or mixed hearing loss with >1 audiograms over time, progressive hearing decline was noted in 8/16, and 26/178 hearing thresholds (15%) progressed. CONCLUSIONS Our findings suggest that audiometric evaluations should be considered for at least a subset of children with NF1, given the higher-than-expected rate of hearing loss in NF1 patients compared to that of the general population.

Incidence of Hearing Loss in Patients with Neurofibromatosis Type 1 at a Tertiary Care Pediatric Hospital